Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
CONCLUSIONS: The available RCT evidence suggests that treatment of MO secondary to BRVO with anti-VEGF improves visual and anatomical outcomes at six and 12 months.
PMID: 32633861 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Shalchi Z, Mahroo O, Bunce C, Mitry D Tags: Cochrane Database Syst Rev Source Type: research
More News: Avastin | Cataracts | Databases & Libraries | Dexamethasone | Diabetes | Endocrinology | Eyes | General Medicine | Lucentis | Ranibizumab Injection | Study | Triamcinolone | Vitamin A